Literature DB >> 1348953

Identification and interpretation of epidermal growth factor and c-erbB-2 overexpression.

B A Gusterson1.   

Abstract

Overexpression of normal cellular genes may be one mechanism by which malignant cells can acquire a selective growth advantage. The epidermal growth factor receptor and the c-erbB-2 protein are members of the erbB family and are good examples of genes that appear to act through this mechanism. Molecular and biochemical analyses of these two proteins also illustrate how studies of growth factors, growth factor receptors and oncogenic retroviruses may lead to new approaches to diagnosis and treatment. In particular, overexpression of these growth factor receptors has identified clinical subgroups that may respond differently to chemotherapy and provides the opportunity for antibody targeted therapy. Overexpression of these proteins can be identified using immunocytochemistry on both histological sections and fine-needle aspirates, thus enabling these parameters to be assessed preoperatively and to be monitored during therapy.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1348953     DOI: 10.1016/0959-8049(92)90429-6

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  10 in total

1.  p185neu is expressed in yolk sac during rat postimplantation development.

Authors:  V Knezevic; R Spaventi; L Poljak; N Slade; A Svajger; K Pavelic
Journal:  J Anat       Date:  1994-08       Impact factor: 2.610

2.  Sox2 targets cyclinE, p27 and survivin to regulate androgen-independent human prostate cancer cell proliferation and apoptosis.

Authors:  F Lin; P Lin; D Zhao; Y Chen; L Xiao; W Qin; D Li; H Chen; B Zhao; H Zou; X Zheng; X Yu
Journal:  Cell Prolif       Date:  2012-04-02       Impact factor: 6.831

3.  MCF-7 breast cancer cells overexpressing transfected c-erbB-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivity in vivo.

Authors:  Y Liu; D el-Ashry; D Chen; I Y Ding; F G Kern
Journal:  Breast Cancer Res Treat       Date:  1995-05       Impact factor: 4.872

4.  EGFR ligand switch in late stage prostate cancer contributes to changes in cell signaling and bone remodeling.

Authors:  Alyse M DeHaan; Natalie M Wolters; Evan T Keller; Kathleen M Woods Ignatoski
Journal:  Prostate       Date:  2009-04-01       Impact factor: 4.104

Review 5.  ER re-expression and re-sensitization to endocrine therapies in ER-negative breast cancers.

Authors:  Joeli A Brinkman; Dorraya El-Ashry
Journal:  J Mammary Gland Biol Neoplasia       Date:  2009-03-05       Impact factor: 2.673

Review 6.  The silent estrogen receptor--can we make it speak?

Authors:  Madhavi Billam; Abigail E Witt; Nancy E Davidson
Journal:  Cancer Biol Ther       Date:  2009-03-15       Impact factor: 4.742

7.  Transcriptomic landscape of breast cancers through mRNA sequencing.

Authors:  Jeyanthy Eswaran; Dinesh Cyanam; Prakriti Mudvari; Sirigiri Divijendra Natha Reddy; Suresh B Pakala; Sujit S Nair; Liliana Florea; Suzanne A W Fuqua; Sucheta Godbole; Rakesh Kumar
Journal:  Sci Rep       Date:  2012-02-14       Impact factor: 4.379

8.  New approaches for cancer treatment: antitumor drugs based on gene-targeted nucleic acids.

Authors:  O A Patutina; N L Mironova; V V Vlassov; M A Zenkova
Journal:  Acta Naturae       Date:  2009-07       Impact factor: 1.845

Review 9.  Oestrogen receptor negativity in breast cancer: a cause or consequence?

Authors:  Vijaya Narasihma Reddy Gajulapalli; Vijaya Lakshmi Malisetty; Suresh Kumar Chitta; Bramanandam Manavathi
Journal:  Biosci Rep       Date:  2016-12-23       Impact factor: 3.840

Review 10.  Glycosylation-Based Serum Biomarkers for Cancer Diagnostics and Prognostics.

Authors:  Alan Kirwan; Marta Utratna; Michael E O'Dwyer; Lokesh Joshi; Michelle Kilcoyne
Journal:  Biomed Res Int       Date:  2015-10-05       Impact factor: 3.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.